Key Inclusion Criteria

          -  Stage II to IV (M0) CSCC, for which surgery would be recommended in routine clinical
             practice. For stage II patients, lesion must be ≥3 cm at the longest diameter.

          -  At least 1 lesion that is measurable by RECIST 1.1

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Adequate organ, bone marrow function, and hepatic function as defined in the protocol

        Key Exclusion Criteria

          -  Solid malignancy within 5 years of the projected enrollment date, or hematologic
             malignancy (including chronic lymphocytic leukemia [CLL]) at any time

          -  Distant metastatic disease (M1), visceral and/or distant nodal

          -  Prior radiation therapy for CSCC

          -  Patients with a condition requiring corticosteroid therapy (>10 mg prednisone/day or
             equivalent) within 14 days of the first dose of study drug.

          -  Patients with active, known, or suspected autoimmune disease that has required
             systemic therapy within 5 years of the projected enrollment date.

          -  History of interstitial lung disease (eg, idiopathic pulmonary fibrosis, organizing
             pneumonia) or active, noninfectious pneumonitis that required immune-suppressive doses
             of glucocorticoids to assist with management.

          -  Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B or
             hepatitis C virus (HBV or HCV) infection; or diagnosis of immunodeficiency

          -  Active tuberculosis

        NOTE: Other protocol-defined Inclusion/Exclusion Criteria apply